Orano Med chooses The Hive for its new headquarters
Villejuif (94800), 30 September 2025 – Kadans, a leading player in real estate development dedicated to innovative ecosystems in Europe, announces the signing of a new lease with Orano Med. This subsidiary of the Orano Group, specialising in the development of targeted alpha therapies in oncology, will establish its headquarters and new research and development (R&D) laboratory within The Hive at Campus Grand Parc in Villejuif.
The fit-out works will precede the arrival of the teams, scheduled for 2026. With this new location, Orano Med is integrating into a rapidly developing innovation district, centred around the Villejuif – Gustave Roussy station (lines M14 and M15) and is driven by the Paris Saclay Cancer Cluster (PSCC), France’s first biocluster dedicated to oncology.
The research laboratory, due to be commissioned in the first half of 2026, will focus on the development of chemical vectors for applications in targeted alpha therapy. It will strengthen Orano Med’s R&D capacities and accelerate the in-house development of innovative new cancer therapies. This new site continues Orano Med’s investment strategy in France.
Within this ecosystem, Orano Med will be based in The Hive, a 25,000 m² hub designed and operated by Kadans Science Partner, a leading European player in cutting-edge scientific real estate. The Hive will host key innovators in oncology research, shaping the diagnostics, treatments, and prevention strategies of tomorrow. Orano Med will join companies such as Orakl Oncology and Sanofi at The Hive.
Sophie Letournel, Director of Strategy, Programmes and Portfolio at Orano Med, said:
“Our move into The Hive in Villejuif will strengthen our ability to develop innovative alpha therapies and accelerate oncology research, while positioning us at the heart of a French ecosystem of excellence dedicated to innovation in this field.”
Elsa Ferrard, Director of Kadans Science Partner France, commented:
“We are very proud to welcome Orano Med. It is an outstanding company that confirms the attractiveness of the site for innovative oncology biotechs.”
Benjamin Garel, CEO of the Paris Saclay Cancer Cluster, added:
“Orano Med is one of the pioneers in targeted internal radiotherapy, one of the most promising modalities in targeted therapies, and we are delighted to welcome them at the heart of this oncology-dedicated cluster.”
